Immune Checkpoint Inhibitor-Associated Scleroderma-Like Syndrome: A Report of a Pembrolizumab-Induced “Eosinophilic Fasciitis-Like” Case and a Review of the Literature

Immune Checkpoint Inhibitor-Associated Scleroderma-Like Syndrome: A Report of a Pembrolizumab-Induced “Eosinophilic Fasciitis-Like” Case and a Review of the Literature

Abstract Immune checkpoint inhibitors are a promising new therapeutic strategy in oncology that aims to eliminate cancer cells by enhancing patients' immune response against tumor antigens. Despite their beneficial effects, immune checkpoint inhibitors are also responsible for a plethora of aut...

Full description

Bibliographic Details
Main Authors: Christina Salamaliki, Elena E. Solomou, Stamatis-Nick C. Liossis
Format: Article
Language:English
Published: Adis, Springer Healthcare 2020-10-01
Series:Rheumatology and Therapy
Subjects:
Checkpoint inhibitors
Eosinophilic fasciitis
Immune-related adverse event
PD-1 inhibitor
Pembrolizumab
Online Access:https://doi.org/10.1007/s40744-020-00246-z

Internet

https://doi.org/10.1007/s40744-020-00246-z

Similar Items